Aussie dollar torn between RBA policy bets and risk appetite trends

Published 06-OCT-2015 09:34 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

As the Reserve Bank convenes for its monthly interest rate decision, domestic monetary policy consideration will return to the spotlight.

It is expected that Reserve Bank Chairman Glenn Stevens will keep the baseline lending rate at 2% with most markets and economists agreeing that no change will occur.

Daily FX Currency Strategist Ilya Spivak says, “An outcome in line with the consensus will see traders combing the policy statement accompanying announcement for guidance on how things ought to evolve going forward. Scheduled commentary from RBA Assistant Governor Guy Debelle and outlook.”

Spivak says that the markets are pricing in at least one cut over the coming 12 months.

“Australian economic news flow has increasingly deteriorated relative to consensus forecasts since the last policy meeting in early September. Survey-based 2015-17 GDP growth forecasts and priced-in medium term inflation expectations derived from bond yields have dropped over the same period. This opens the door for a dovish shift in RBA rhetoric to weigh on the Aussie.”

Meanwhile the return of homegrown catalysts will not be accompanies by a slowdown in external event risk.

“The US Federal Reserve and the ECB will both release minutes from their latest policy meetings. Traders will dutifully scour both releases to gauge the degree of concern about global growth dynamic policymakers.”

Yann Quelenn, Market Analyst, Swissquote agrees with Spivak’s sentiment. She says, “Markets are currently pricing in a 90% probability that the rates are going to be unchanged. However, there is a decent likelihood, estimated at 40%, that a rate cut will happen by next year.

“The fundamentals are improving. Inflation data, released this morning from the institution TD Securities, increased in September by 0.3%m/m. The annualised figure has increased also toward by 2% year-on-year. The Australian dollar has devalued and remains currently very low, which has taken some of the pressure off the country by boosted exports. Nevertheless, one of the major partners for commodities is China and the lingering weak commodity prices are weighing on the Australian growth. In particular, the mining industry is suffering and investments have declined sharply. It seems that the positive effects of a weak currency are not offsetting the growth deceleration due to negative world market conditions.

Spivak says cross-market trading patterns following last week’s dismal US employment report suggest dovish rhetoric may prove supportive for risk appetite, offering support for the sentiment-linked Australian currency.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free